Departments of Intensive Care.
Hospital Pharmacy, and.
Ther Drug Monit. 2022 Feb 1;44(1):224-229. doi: 10.1097/FTD.0000000000000891.
Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is a cost determinant in the ICU.
Patients included in the EXPAT trial were divided into target attainment and target nonattainment based on serum antibiotic levels. All hospital costs were extracted from the hospital administration system and categorized.
In total, 79 patients were included in the analysis. Target attainment showed a trend toward higher total ICU costs (€44,600 versus €28,200, P = 0.103). This trend disappeared when correcting for ICU length of stay (€2680 versus €2700). Renal replacement therapy was the most important cost driver.
Target attainment for beta-lactam antibiotics shows a trend toward higher total costs in ICU patients, which can be attributed to the high costs of a long stay in the ICU and renal replacement therapy.
优化β-内酰胺类抗生素治疗是一种很有前途的方法，可以缩短重症监护病房（ICU）的住院时间，从而降低 ICU 的成本。我们利用 EXPAT 试验的数据来确定 ICU 中β-内酰胺类抗生素目标达标是否是成本决定因素。
根据血清抗生素水平，将 EXPAT 试验中的患者分为目标达标和目标未达标两组。从医院管理系统中提取所有的住院费用，并进行分类。
共有 79 名患者纳入分析。目标达标组的 ICU 总费用有升高趋势（€44600 比 €28200，P=0.103）。当校正 ICU 住院时间后（€2680 比 €2700），这种趋势消失了。肾脏替代疗法是最重要的成本驱动因素。
β-内酰胺类抗生素的目标达标与 ICU 患者的总费用升高呈趋势相关，这可归因于 ICU 住院时间长和肾脏替代疗法的高成本。
